Prostate tumours-TR-colour Doppler evaluation & correlation with PSA & Histo-Pathology
Keywords:
BPH, prostate carcinoma, TRUS, colour Doppler, PSAAbstract
Introduction: Prostate gland is site of two common diseases in ageing man, benign prostatic hyperplasia and prostate cancer. Advanced TRUS techniques may help in better tissue characterization, hence in armamentarium of non- invasive techniques. TRUS provides direct visualisation of echopattern, site and size of lesion and also helps in proper interpretation of focal prostatic lesions. Material and methods: A Prospective study was conducted in Dept. of Radio-Diagnosis in 50 patients who were suspected to have prostatic tumours by clinical & TAS examination were subjected TRUS and colour Doppler followed by their histopathological correlation to study sensitivity and specificity of TRUS and colour Doppler for diagnosis of prostatic tumours. Results: Majority of patients 03 out of 07 pts with cancer belonged to age group of 61- 70 years. Majority of patients 30 out of 43 (70%) of BPH cases belonged to age group of 61-80 yrs. At age of 80 yrs, of BPH patients are found to be 35 0f 43 (81.4%). This study comprised of 50 patients. Among 50 patients diagnosed as prostatic tumours by clinical examination and imaging out of which 07 cases diagnosed as cancer & rest 43 cases to be benign by histopathological examination. TRUS correctly diagnosed 45 patients wrongly diagnosed 05. So TRUS is accurate in diagnosing 90% of prostatic tumours. TRUS with colour Doppler correctly diagnosed 47 patients wrongly diagnosed 05. So it is accurate in diagnosing 94% of prostatic tumours. Conclusion: TRUS with colour Doppler proves to be a valuable, cost effective and non invasive initial modality of imaging in accurately evaluating morphologic distribution of prostatic tumours. Technological advances in imaging have created a new role for various tests in management of prostate cancers. Advances in imaging exploit biology of disease, and in doing so, allow more accurate detection of location, extent, and aggressiveness of malignancy. In this article, we review current status of imaging in prostate cancer diagnosis, staging, and monitoring of recurrence.
References
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014 Jan-Feb; 64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7.
Syrigos KN, Karapanagiotou E, Prostate cancer in the elderly. Anticancer Res. 2005 Nov-Dec; 25 (6C): 4527-33. https://www.ncbi.nlm.nih.go
Sharma S, Imaging and intervention in prostate cancer: Current perspectives and future trends. Indian J Radiol Imaging. 2014 Apr; 24(2):139-48. doi: 10.4103/0971-3026.134399. https: //www. ncbi.nlm. nih.gov
Boesen LMultiparametric MRI in detection and staging of prostate cancer. Dan Med J. 2017 Feb; 64(2). pii: B5327.
Heijmink S, van Moerkerk H, Kiemeney L, et al. A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer. Eur Radiol. 2006; 16(4):927-938.
Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F; European Association of Urology. EAU guidelines on prostate cancer. Eur Urol. 2005 Oct; 48(4):546-51.
Djavan B, Margreiter M. Biopsy standards for detection of prostate cancer. World J Urol. 2007; 25: 11–17.
Novel contrast-enhanced ultrasound imaging in prostate cancer. Smeenge M, Mischi M, Laguna Pes MP, de la Rosette JJ, Wijkstra H World J Urol. 2011 Oct; 29(5):581-7.
Trabulsi EJ, Sackett D, Gomella LG, Halpern EJ. Enhanced Transrectal Ultrasound Modalities in the Diagnosis of Prostate Cancer. Urology. 2010; 76: 1025–1033.
Heijmink SW, Barentsz JO. Contrast-enhanced versus systematic transrectal ultrasound-guided prostate cancer detection: An overview of techniques and a systematic review. Eur J Radiol. 2007; 63:310–316.
Heijmink SW, van Moerkerk H, Kiemeney LA, Witjes JA, Frauscher F, Barentsz JO. A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer. Eur Radiol. 2006; 16:927–938.
Mitterberger M, Horninger W, Pelzer A, Strasser H, Bartsch G, Moser P, Halpern EJ, Gradl J, Aigner F, Pallwein L, Frauscher F. A Prospective Randomized Trial Comparing Contrast-Enhanced Targeted Versus Systematic Ultrasound Guided Biopsies: Impact on Prostate Cancer Detection. Prostate. 2007; 67: 1537–1542.
Halpern EJ, Ramey JR, Strup SE, Frauscher F, McCue P, Gomella LG. Detection of Prostate Carcinoma with Contrast-Enhanced Sonography Using Intermittent Harmonic Imaging. Cancer. 2005; 104: 2373–2383.
Mitterberger MJ, Aigner F, Horninger W, Ulmer H, Cavuto S, Halpern EJ, Frauscher F. Comparative efficiency of contrast enhanced colour Doppler ultrasound targeted versus systematic biopsy for prostate cancer detection. Eur Radiol. 2010; 20: 2791–2796.
Yuen JS. Comparison of contrast enhanced color Doppler targeted biopsy with convertional systematic biopsy:impact on prostate cancer detection. J Urol. 2003; 170:192–3.
Aigner F, Pallwein L, Mitterberger M, Pinggera GM, Mikuz G, Horninger W, Frauscher F. Contrastenhanced ultrasonography using cadence-contrast pulse sequencing technology for targeted biopsy of the prostate. BJU Int. 2008; 103:458–463.
Halpern EJ, Rosenberg M, Gomella LG. Prostate cancer: contrast-enhanced us for detection. Radiology. 2001 Apr; 219(1):219-25.
Matsumoto K, Nakagawa K, Hashiguchi A, Kono H, Kikuchi E, Nagata H, Miyajima A, Oya M. Contrastenhanced Ultrasonography of the Prostate with Sonazoid. Jpn J Clin Oncol. 2010; 40:1099–104.
Zhao HX, Xia CX, Yin HX, Guo N, Zhu Q. The value and limitations of contrast-enhanced transrectalultrasonography for the detection of prostate cancer. Eur J Radiol. 2013; 82:e641–647.
Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, Patel A, Richie JP, Walsh PC, Scardino PT, Lange PH, Gasior GH, Loveland KG, Bray KR. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000 Aug 1; 56(2):255-60.
Humera Khan et al, determinants of prostate cancer, Birmingham prostatic neoplasm association study Eur J Hum Genet. 2011 Jan; 19 (1):118-120 etheses. bham.ac.uk
Kuligowska E1, Barish MA Predictors of prostate carcinoma: accuracy of gray-scale and color Doppler US and serum markers. Radiology. 2001 Sep; 220(3): 757-64.
Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W, Begaud B, Berges R, Borkowski A, Chappel CR, Costello A, Dobronski P, Farmer RD, Jiménez Cruz F, Jonas U, MacRae K, Pientka L, Rutten FF, van Schayck CP, Speakman MJ, Sturkenboom MC, Tiellac P, Tubaro A, Vallencien G, Vela Navarrete R;Triumph Pan European Expert Panel. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project. Eur Urol. 2002 Oct; 42(4):323-8.
Shigeno K, Igawa M, Shiina H, Wada H, Yoneda T. The role of colour Doppler ultrasonography in detecting prostate cancer. BJU Int. 2000 Aug; 86(3):229-33.
Sen J1, Choudhary L Role of colour Doppler imaging in detecting prostate cancer. Asian J Surg. 2008 Jan; 31(1):16-9. doi: 10.1016/S1015-9584(08) 60049-4.
Abdellaoui A, Iyengar S, Freeman S. Imaging in prostate cancer. Future Oncol. 2011 May; 7(5):679-91. doi: 10.2217/fon.11.43.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Biomedical Review follows the Creative Commons CC-BY license (Attribution). It means Authors can use, reuse and build upon the material published in the journal but only for non-commercial purposes. Every article published in the Journal clearly mentioned licensing terms between author/authors and publisher (Siddharth Health Research and Social Welfare Society) as the logo of Creative Commons CC-BY license (Attribution) https://creativecommons.org/licenses/by/4.0/.